CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues:
Total revenues	$ 7,769	$ 7,545	$ 21,518	$ 21,185
Costs and expenses:
Cost of goods sold	1,569	1,574	4,610	4,670
Research and development expenses	1,346	1,395	4,215	4,266
Acquired in-process research and development expenses	170	505	485	4,674
In-process research and development impairments	0	1,750	190	4,180
Selling, general and administrative expenses	1,357	1,433	3,980	4,184
Total costs and expenses	4,442	6,657	13,480	21,975
Operating income (loss)	3,327	888	8,038	(790)
Interest expense	256	238	769	728
Other (income) expense, net	(569)	(306)	(449)	(41)
Income (loss) before income taxes	3,641	956	7,718	(1,477)
Income tax expense (benefit)	589	(297)	1,391	(174)
Net income (loss)	3,052	1,253	6,327	(1,303)
Net income attributable to noncontrolling interest	0	0	0	0
Net income (loss) attributable to Gilead	$ 3,052	$ 1,253	$ 6,327	$ (1,303)
Basic earnings (loss) per share attributable to Gilead (in dollars per share)	$ 2.46	$ 1.00	$ 5.08	$ (1.04)
Diluted earnings (loss) per share attributable to Gilead (in dollars per share)	$ 2.43	$ 1.00	$ 5.04	$ (1.04)
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares)	1,243	1,247	1,245	1,247
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares)	1,254	1,254	1,256	1,247
Product sales
Revenues:
Total revenues	$ 7,345	$ 7,515	$ 21,013	$ 21,074
Royalty, contract and other revenues
Revenues:
Total revenues	$ 424	$ 30	$ 505	$ 111

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Operating Activities:
Net income (loss):	$ 6,327	$ (1,303)
Adjustments to reconcile Net income (loss) to Net cash provided by operating activities:
Depreciation expense	280	286
Amortization expense	1,793	1,788
Stock-based compensation expense	664	613
Deferred income taxes	282	(1,465)
Net (gain) loss from equity securities	(198)	148
Acquired in-process research and development expenses	485	4,674
In-process research and development impairments	190	4,180
Other, net	213	294
Changes in operating assets and liabilities:
Accounts receivable, net	(546)	67
Inventories	(913)	(200)
Prepaid expenses and other	(275)	(113)
Accounts payable	(37)	348
Income tax assets and liabilities, net	(1,974)	(1,268)
Accrued and other liabilities	401	(197)
Net cash provided by operating activities	6,692	7,853
Investing Activities:
Purchases of marketable debt securities	(2,557)	(244)
Proceeds from sales of marketable debt securities	514	2,265
Proceeds from maturities of marketable debt securities	32	327
Acquisitions, including in-process research and development, net of cash acquired	(461)	(4,765)
Purchases of equity securities	(119)	(453)
Purchases of property, plant and equipment	(358)	(376)
Other investing activities, net	(9)	23
Net cash used in investing activities	(2,958)	(3,224)
Financing Activities:
Proceeds from issuances of common stock	376	249
Repurchases of common stock under repurchase programs	(1,692)	(800)
Repayments of debt and other obligations	(1,780)	(1,963)
Payments of dividends	(3,009)	(2,945)
Other financing activities, net	(377)	(234)
Net cash used in financing activities	(6,482)	(5,693)
Effect of exchange rate changes on cash and cash equivalents	87	15
Net change in cash and cash equivalents	(2,661)	(1,049)
Cash and cash equivalents at beginning of period	9,991	6,085
Cash and cash equivalents at end of period	$ 7,330	$ 5,037

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 7,330	$ 9,991
Short-term marketable debt securities	19	0
Accounts receivable, net	5,095	4,420
Inventories	1,785	1,710
Prepaid and other current assets	3,645	3,052
Total current assets	17,874	19,173
Property, plant and equipment, net	5,500	5,414
Long-term marketable debt securities	2,005	0
Intangible assets, net	17,970	19,948
Goodwill	8,314	8,314
Deferred tax assets	1,998	2,378
Other long-term assets	4,873	3,769
Total assets	58,533	58,995
Current liabilities:
Accounts payable	808	833
Accrued rebates	4,931	3,892
Current portion of long-term debt, net	2,806	1,815
Other current liabilities	3,752	5,464
Total current liabilities	12,298	12,004
Long-term debt, net	22,135	24,896
Long-term income taxes payable	866	830
Deferred tax liabilities	597	724
Other long-term liabilities	1,182	1,295
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding	0	0
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,242 and 1,246 shares issued and outstanding, respectively	1	1
Additional paid-in capital	8,678	7,700
Accumulated other comprehensive income	36	132
Retained earnings	12,825	11,497
Total Gilead stockholders’ equity	21,540	19,330
Noncontrolling interest	(84)	(84)
Total stockholders’ equity	21,456	19,246
Total liabilities and stockholders’ equity	$ 58,533	$ 58,995